ACE — Ascelia Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK71.37m
- SEK33.84m
Brief: Ascelia Pharma Q1 EBIT SEK -20.3 Million
Brief: Ascelia Pharma Q4 Operating Result Loss Widens to Sek 21.9 Mln
Brief: Ascelia Pharma Q4 EBIT SEK -21.9 Million
Brief: Ascelia Pharma Granted Chinese Patent For Second-Generation Orviglance
Brief: Ascelia Pharma Q3 Oper Loss Narrows To SEK 17.8 Mln
Brief: Ascelia Pharma Resolves On Convertibles Issue Of SEK 7.5 Mln
Brief: Ascelia Pharma Gets SEK 105 Mln In Rights Issue
Brief: Ascelia Pharma To Receive Gross Proceeds Of SEK 105 Mln Through Rights Issue
Brief: Ascelia Pharma Q2 EBIT SEK -11.3 Million
Brief: Ascelia Pharma's Q2 Operating Loss Down At SEK 11.3 Mln
Brief: Ascelia Pharma Sets Subscription Price In Rights Issue At SEK 5.07/Unit
Brief: Ascelia Pharma Resolves On Rights Issue Of About SEK 105 Mln
Brief: Ascelia Pharma Says To Focus On Bringing Orviglance Through Regulatory Approval Process
Brief: Ascelia Pharma Q1 EBIT SEK -16.7 Million
Brief: Ascelia Pharma Meets Primary Endpoint In Orviglance Phase 3 Study
Brief: Ascelia Pharma Draws Down SEK 15 Mln Second Tranche Under Existing Loan Facility
Brief: Ascelia Pharma Q4 Operating Loss Narrows To SEK 11.1 Mln
Brief: Ascelia Pharma Q3 Operating Loss Narrows To SEK -21.4 Mln
Brief: Ascelia Pharma Reduces Organization To Reach SPARKLE Headline Results